Cadence Pharmaceuticals Announces Supply Agreement with Laboratorios Grifols for OFIRMEV Injection

Cadence Pharmaceuticals (NASDAQ: CADX ) today announced a new supply agreement with Laboratorios Grifols, S.A. for the development, manufacture and supply of commercial quantities of OFIRMEV (acetaminophen) injection in flexible plastic bags. Previously, Cadence announced the extension of its supply arrangement for OFIRMEV in glass vials with Lawrence Laboratories,